Abstract
Currently, a search is underway for non-drug biologically active agents that help restore impaired metabolism in metabolic syndrome. The attention of many researchers is drawn to L-carnitine and its role in the metabolism of fats and carbohydrates in both normal and pathological conditions.
The review is devoted to an urgent topic the theoretical justification of increasing the biogenic potential of drinking mineral waters in order to use them in the non-drug treatment of metabolic syndrome. The choice of a biologically active substance for the modification of drinking mineral waters, namely, L-carnitine, is based on its direct involvement in the energy exchange of body cells.
L-carnitine plays an irreplaceable role in lipid metabolism: it participates in the transport of fatty acids and products of their incomplete oxidation across the mitochondrial membrane, potentiating -oxidation of long-chain fatty acids, which leads to the activation of energy metabolism in various tissues. Thus, it can be assumed that the addition of L-carnitine to the diet of patients with metabolic syndrome and type 2 diabetes mellitus may be an effective tool in the treatment and prevention of the progression of these diseases.
The data of experimental and clinical studies justifying the preventive effect of drinking mineral waters were analyzed. In addition, we have conducted searching for scientific publications over the past 5 years in the electronic databases PubMed, Web of Science, e-Library on the study of L-carnitine and drinking mineral waters of various compositions, taking into account their influence on the components of metabolic syndrome. The search terms provided criteria that included full text, related data, clinical trials, meta-analysis, randomized controlled trials, and systematic reviews.
Based on the results of independent scientific studies, it is unambiguous to conclude that there is both a direct (due to dissolved ions) and a more complex (mediated through regulatory systems) effect of mineral waters on impaired metabolism caused by magnesium and calcium deficiency in this group of patients.
Reference30 articles.
1. COMORBIDITIES IN PRACTICE. CLINICAL GUIDELINES
2. Nedogoda SV, Vertkin AL, Naumov AV, et al. Obesity and comorbid pathology in the practice of a polyclinic doctor. Part I: definition, diagnostics. Clinical recommendations. Outpatient Admission. 2016;2(4):21–32. (In Russ).
3. COVID-19, diabetes mellitus and ACE2: The conundrum
4. Dudinskaya EN, Machekhina LV. Insulin resistance as a link between diabetes mellitus, obesity, dyslipidemia and cardiovascular diseases. Effective Pharmacotherapy. 2021;17(5):6–8. (In Russ).
5. Smirnova MD. Nonalcoholic fatty liver disease — an unaccounted risk factor for atherosclerosis. Medical Review. 2018;2(4):8–11. (In Russ).